CervoMed Inc. CRVO 深 沪
已收盘 02-06 16:00:00 美东时间
5.31
+0.710
+15.43%
华盛通- 最 高5.65
- 今 开4.60
- 成交量 10.58万股
- 最 低 4.60
- 昨 收 4.60
- 总市值 4913.19万
- 52周最高 16.94
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 1.92
- 委 比 -11.11%
- 总股本 925.27万
- 历史最高 17437.50
- 量 比 1.29
- 振 幅 22.83%
- 历史最低 1.80
- 每 手 1
- 风险率 2.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Managing Biotech Risk With Insider Clues
Biotech stocks have a way of making smart people do dumb things. It starts inno...
01-16 00:32
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Cantor Fitzgerald Initiates Coverage On CervoMed with Overweight Rating
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on CervoMed (NASDAQ:CRVO) with a Overweight rating.
2025-12-18 21:02
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
2025-12-18 20:07
CervoMed's Neflamapimod, Oral, Small Molecule, Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, To Be Featured In Two Presentations At CTAD 2025
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLBNew data demonstrating the utility of
2025-11-24 20:10
CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by 72.13 percent. This is a 52.73 percent decrease over losses of $(0.55) per share from the
2025-11-10 20:21
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.
2025-11-04 21:41
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CervoMed Inc. announced the appointment of David Quigley to its Board of Directors. Quigley, a former Senior Partner at McKinsey & Company, has extensive experience in life sciences and private equity. His加入 will support CervoMed as it prepares for Phase 3 trials and commercialization of neflamapimod, a potential treatment for Dementia with Lewy bodies (DLB). Quigley's expertise will help advance the company's clinical and business development go...
2025-10-28 12:00
